+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lupus Therapeutic - Global Market Trajectory & Analytics

  • ID: 5309789
  • Report
  • April 2021
  • Region: Global
  • 130 pages
  • Global Industry Analysts, Inc
Global Lupus Therapeutic Market to Reach $3.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Lupus Therapeutic estimated at US$2.1 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 8.6% over the analysis period 2020-2027. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is projected to record a 7.9% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Corticosteroids segment is readjusted to a revised 8.3% CAGR for the next 7-year period.



The U.S. Market is Estimated at $631.7 Million, While China is Forecast to Grow at 8.1% CAGR

The Lupus Therapeutic market in the U.S. is estimated at US$631.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$661.6 Million by the year 2027 trailing a CAGR of 8.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7% CAGR.

Immunosuppressant Drugs Segment to Record 9.1% CAGR

In the global Immunosuppressant Drugs segment, USA, Canada, Japan, China and Europe will drive the 9.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$262.9 Million in the year 2020 will reach a projected size of US$485.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$440.4 Million by the year 2027.

Select Competitors (Total 31 Featured):
  • ADMA Biologics, Inc.
  • Amgen, Inc.
  • Anthera Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • Biogen, Inc.
  • Biotest AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Immunomedics, Inc.
  • Kedrion Biopharma, Inc.
  • LFB Group
  • MedImmune, LLC
  • Merck KgaA
  • Novartis International AG
  • Pfizer, Inc.
  • Shire PLC
  • Takeda Pharmaceuticals Company Ltd.
  • UCB SA
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Lupus Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Lupus Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Lupus Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Immunosuppressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Antimalarial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Antimalarial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Antimalarial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for BLyS-Specific Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for BLyS-Specific Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for BLyS-Specific Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 19: World Current & Future Analysis for Biologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Biologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for Biologicals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 22: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 23: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 25: USA Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: USA Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: USA 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • CANADA
  • Table 28: Canada Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: Canada Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: Canada 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 31: Japan Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Japan Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: Japan 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • CHINA
  • Table 34: China Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: China Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: China 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 37: Europe Current & Future Analysis for Lupus Therapeutic by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 38: Europe Historic Review for Lupus Therapeutic by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: Europe 15-Year Perspective for Lupus Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 40: Europe Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 41: Europe Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: Europe 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 43: France Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: France Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: France 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 46: Germany Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: Germany Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: Germany 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • ITALY
  • Table 49: Italy Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: Italy Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: Italy 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 52: UK Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 53: UK Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 54: UK 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 55: Rest of Europe Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: Rest of Europe Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 57: Rest of Europe 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 58: Asia-Pacific Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 59: Asia-Pacific Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 60: Asia-Pacific 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 61: Rest of World Current & Future Analysis for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: Rest of World Historic Review for Lupus Therapeutic by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 63: Rest of World 15-Year Perspective for Lupus Therapeutic by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 31
Note: Product cover images may vary from those shown
Adroll
adroll